(Bloomberg) — Wall Street analysts and specialists are weighing the possibility that Pfizer Inc. and BioNTech SE may file their Covid-19 vaccine candidate with regulators by October after the pair said a late-stage Covid-19 vaccine study kicked off on Monday evening.Pfizer rose Tuesday on the announcement with its German partner, just hours after similar news from Moderna Inc. With AstraZeneca Plc already in Phase 3, it’s a “three-horse race,” Jared Holz said from the Jefferies health-care trading desk. “The government involvement makes us think we could hear anecdotal reports of trial progress even before the interim data is available later in the year,” he wrote to clients.Holz expects at least one vaccine will get an emergency use authorization before November, which many have thought may give President Donald Trump a new foothold in the election as his polling numbers slip in favor of Democratic contender Joe Biden. But not everyone is as optimistic over an October timeline.UBS analyst Navin Jacob said Pfizer’s program may have a “slight edge” over Moderna, but a Centers for Disease Control adviser that Jacob spoke with cast doubts about the October target. Some on Wall Street also reflected surprise that the vaccine candidate Pfizer and BioNTech selected was not the same shot that investors had seen detailed data from.Pfizer rose as much as 2.7% on Tuesday after posting second-quarter earnings that topped estimates and increasing its sales forecast. UBS, Navin JacobJacob spoke to an expert from the CDC’s Advisory Committee on Immunization Practices, who said an autumn 2020 readout from a Phase 3 trial would be “a stretch” as the rate of new infections for patients in the trial would likely be too slow. He predicted an initial look at results was more likely to come in the first half of next year.Jacob said Pfizer’s international study may have an advantage over Moderna’s U.S. based study if the trial is in areas where Covid-19 is quickly spreading. He was also positive on the results seen so far which seem to indicate the BNT162 program “may have slightly better efficacy.”SVB Leerink, Geoffrey PorgesThe selection of BNT162b2, “though a clear possibility,” according to Porges, “was somewhat of a surprise given the companies shared detailed data for BNT162b1, which vaccinates against the receptor binding domain (RBD) of the spike protein.” He expects the decision was driven by potentially better immune responses in older adults.“All leading companies are now targeting the spike protein, highlighting correlated clinical risk and long-term market erosion risk,” Porges said. That concentration calls into question the long-term viability of a market for these vaccines, he said.Pfizer’s vaccine appears to be enrolling in hotspots amid state reopenings, “inclusion of all these sites could increase the speed for enrollment, as well as shorten the time for accumulating enough events.”Barclays, Carter Gould“We previously viewed recent BNT162b1 data as the most promising vaccine candidate to date, and b2 at least directionally appears to have a better profile,” though the analyst notes more details are needed.He expects further characterization of BNT162b2, as well as details on the recent $1.95 billion contract with the U.S., and EU efforts to secure access, to be discussed on Tuesday’s call.Pfizer’s call is set to start at 10 a.m. in New York.(Updates shares in fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
from Yahoo Finance https://ift.tt/2BB5gXG
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
Trump on Friday signed four executive orders aimed at lowering the prices Americans pay for prescription drugs, as he faces an uphill re-election battle and criticism over his handling of the coronavirus pandemic. “These new executive orders could force us to rethink those plans, consider job reductions and add to the economic and health anxiety already widely felt in our country,” Bourla said on the company’s earnings conference call.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
We can readily understand why investors are attracted to unprofitable companies. For example, Intra-Cellular Therapies…
Goldman Sachs has a new target price for gold — and in a new note it raised concerns about the dollar as well. The post Goldman Sachs boosts gold price target, says the U.S. dollar's reserve status is at risk appeared first on The Block.
TORONTO, July 28, 2020 /CNW/ – Argonaut Gold Inc. (TSX: AR) (the "Company", "Argonaut Gold" or "Argonaut") is pleased to announce drill results from Phase Two of its drill campaign specifically targeting high-grade mineralization below the proposed pit at its 100% owned Magino property in Ontario, Canada, including 6.
Miller Value Partners recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Opportunity Equity Fund posted a return of 47.02% for the quarter (net of fees), outperforming its benchmark, the S&P 500 Index which returned 20.54% in the same quarter. You should check out Miller Value Partners' top […]
For us, stock picking is in large part the hunt for the truly magnificent stocks. But when you hold the right stock…